Skip to main content
SpringerLink
Log in

Effect of sabcomeline on muscarinic and dopamine receptor binding in intact mouse brain

  • Original Articles
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Sabcomeline [(R,-(Z)-(+)-α-(methoxyiamino)-1-azabicyclo[2.2.2.]octane-3-acetonitrile)] is a potent and functionally selective muscarinic M1 receptor partial agonist. However, little is known of the binding properties of sabcomeline underin vivo conditions. In this study, muscarinic receptor occupancy by sabcomeline in mouse brain regions and heart was estimated using [3H]quinuclidinyl benzilate (QNB) and [3H]N-methylpiperidyl benzilate (NMPB) as radioligands. In the cerebral cortex, hippocampus, and striatum, the estimated IC50 value of sabcomeline for [3H]NMPB binding was almost 0.2 mg/kg. Sabcomeline was not a selective ligand to M1 receptors as compared with biperidenin vivo. In the cerebral cortex, maximum receptor occupancy was observed about 1 hr after intravenous injection of sabcomeline (0.3 mg/kg), and the binding availability of mACh receptors had almost returned to the control level by 3–4 hr. These findings indicated that the binding kinetics of sabcomeline is rather rapid in mouse brain. Examination of dopamine D2 receptor binding revealed that sabcomeline affected the kinetics of both [3H]raclopride and [3H]N-methylspiperone (NMSP) binding in the striatum. It significantly decreased the k3 and k4 of [3H]raclopride binding resulting in an increase in binding potential (BP=k3/k4=Bmax/Kd) in sabcomeline-treated mice, and an approximately 15% decrease in k3 of [3H]NMSP binding was also observed. Although the mechanism is still unclear, sabcomeline altered dopamine D2 receptor affinity or availability by modulations via neural networks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain.Science 1982; 215: 1237–1239.

    Article  PubMed  CAS  Google Scholar 

  2. Coyle, JT, Price DL, DeLong MR. Alzheimer’s disease: a disorder of cortical cholinergic innervation.Science 1983; 219: 1184–1190.

    Article  PubMed  CAS  Google Scholar 

  3. Lehericy S, Hirsch EC, Cervera Pierot P, Hersh LB, Bakchine S, Piette F, et al. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer’s disease.J Comp Neurol 1993; 330: 15–31.

    Article  PubMed  CAS  Google Scholar 

  4. Mash DC, Flynn DD, Potter LT. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer’s disease and experimental cholinergic denervation.Science 1985;228: 1115–1117.

    Article  PubMed  CAS  Google Scholar 

  5. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer’s disease.J Neurochem 1988; 50: 1914–1923.

    Article  PubMed  CAS  Google Scholar 

  6. Probst A, Cortes R, Ulrich J, Palacios JM. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer’s disease: an autoradiographic study.Brain Res 1988; 450: 190–201.

    Article  PubMed  CAS  Google Scholar 

  7. London JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, et al. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.J Pharmacol Exp Ther 1997; 283: 1059–1068.

    Google Scholar 

  8. Hatcher JP, Loudon JM, Hagan JJ, Clark MS. Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.Psychopharmacology 1998; 138: 275–282.

    Article  PubMed  CAS  Google Scholar 

  9. Hodges H, Peters S, Gray JA, Hunter AJ. Counteractive effects of a partial (sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area.Behav Brain Res 1999; 99: 81–92.

    Article  PubMed  CAS  Google Scholar 

  10. Harries MH, Samson NA, Cilia J, Hunter AJ. The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset.Br J Pharmacol 1998; 124: 409–415.

    Article  PubMed  CAS  Google Scholar 

  11. Shinotoh H, Asahina M, Inoue O, Suhara T, Hirayama K, Tateno Y. Effects of trihexyphenidyl andl-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography.J Neural Transm Park Dis Dement Sect 1994; 7: 35–46.

    Article  PubMed  CAS  Google Scholar 

  12. Bolden, C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells.J Pharmacol Exp Ther 1992; 260: 576–580.

    PubMed  CAS  Google Scholar 

  13. Hosoi R, Kobayashi K, Watanabe Y, Inoue O. Evaluation ofin vivo binding properties of3H-NMPB and3H-QNB in mouse brain.J Neural Transm 1999; 106: 583–592.

    Article  PubMed  CAS  Google Scholar 

  14. Dewey, SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.Proc Natl Acad Sci USA 1993; 90: 11816–11820

    Article  PubMed  CAS  Google Scholar 

  15. Kobayashi K, Inoue O. An increase in thein vivo binding of [3H]SCH 23390 induced by MK-801 in the mouse striatum.Neuropharmacology 1993; 32: 341–348.

    Article  PubMed  CAS  Google Scholar 

  16. Patlak, CS, Blasberg RG. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. Generalizations.J Cereb Blood Flow Metab 1985; 5: 584–590.

    PubMed  CAS  Google Scholar 

  17. Wood MD, Murkitt KL, Ho M, Watson JM, Brown F, Hunter AJ, et al. Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry.Br J Pharmacol 1999; 126: 1620–1624.

    Article  PubMed  CAS  Google Scholar 

  18. Levey AI. Immunological localization of m1–m5 muscarinic acetylcholine receptors in peripheral tissues and brain.Life Sci 1993; 52: 441–448.

    Article  PubMed  CAS  Google Scholar 

  19. Wei J, Walton EA, Milici A, Buccafusco JJ. m1–m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC.J Neurochem 1994; 63: 815–821.

    Article  PubMed  CAS  Google Scholar 

  20. Tice MA, Hashemi T, Taylor LA, McQuade RD. Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age.Brain Res Dev Brain Res 1996; 92: 70–76.

    Article  PubMed  CAS  Google Scholar 

  21. Stengel PW, Cohen ML. Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline.J Pharmacol Exp Ther 2001; 296: 818–824.

    PubMed  CAS  Google Scholar 

  22. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) andin vivo microdialysis.J Neurosci 1995; 15: 821–829.

    PubMed  CAS  Google Scholar 

  23. Smith GS, Dewey SL, Brodie JD, Logan J, Vitkun SA, Simkowitz P, et al. Serotonergic modulation of dopamine measured with [11C]raclopride and PET in normal human subjects.Am J Psychiatry 1997; 154: 490–496.

    PubMed  CAS  Google Scholar 

  24. Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA, et al. GABAergic inhibition of endogenous dopamine release measuredin vivo with11C-raclopride and positron emission tomography.J Neurosci 1992; 12: 3773–3780.

    PubMed  CAS  Google Scholar 

  25. Smith GS, Schloesser R, Brodie JD, Dewey SL, Logan J, Vitkun SA. et al. Glutamate modulation of dopamine measuredin vivo with positron emission tomography (PET) and11C-raclopride in normal human subjects.Neuropsychopharmacology 1998; 18: 18–25.

    Article  PubMed  CAS  Google Scholar 

  26. Dewey SL, Smith GS, Logan J, Brodie JD, Fowler JS, Wolf AP. Striatal binding of the PET ligand11C-raclopride is altered by drugs that modify synaptic dopamine levels.Synapse 1993; 13: 350–356.

    Article  PubMed  CAS  Google Scholar 

  27. Endres CJ, Kolachana BS, Saunders RC, Su T, Weinberger D, Breier A. et al. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies.J Cereb Blood Flow Metab 1997; 17: 932–942.

    Article  PubMed  CAS  Google Scholar 

  28. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N. Is synaptic dopamine concentration the exclusive factor which alters thein vivo binding of [11C]raclopride?: PET studies combined with microdialysis in conscious monkeys.Brain Res 1999; 841: 160–169.

    Article  PubMed  CAS  Google Scholar 

  29. Opacka Juffry J, Ahier RG, Cremer JE. Nomifensineinduced increase in extracellular striatal dopamine is enhanced by isoflurane anaesthesia.Synapse 1991; 7: 169–171.

    Article  Google Scholar 

  30. Kobayashi K, Inoue O, Watanabe Y, Onoe H, Langstrom B. Difference in response of D2 receptor binding between11C-N-methylspiperone and11C-raclopride against anesthetics in rhesus monkey brain.J Neural Transm Gen Sect 1995; 100: 147–151.

    Article  PubMed  CAS  Google Scholar 

  31. Tsukada H, Harada N, Nishiyama S, Ohba H, Kakiuchi T. Cholinergic neuronal modulation alters dopamine D2 receptor availabilityin vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain.J Neurosci 2000; 20: 7067–7073.

    PubMed  CAS  Google Scholar 

  32. Kobayashi K, Gee A, Hosoi R, Inoue O. Changes in apparentin vivo binding of [3H]raclopride and [3H]N-methylspiperone induced by oxotremorine.J Neural Transm 1998; 105: 1193–1197.

    Article  PubMed  CAS  Google Scholar 

  33. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.Synapse 1989; 3: 96–97.

    Article  PubMed  CAS  Google Scholar 

  34. Ross SB, Jackson DM. Kinetic properties of the accumulation of3H-raclopride in the mouse brainin vivo.Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 6–12.

    PubMed  CAS  Google Scholar 

  35. Hall H, Wedel I, Halldin C, Kopp J, Farde L. Comparison of thein vitro receptor binding properties ofN-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes.J Neurochem 1990; 55: 2048–2057.

    Article  PubMed  CAS  Google Scholar 

  36. Young LT, Wong DF, Goldman S, Minkin E, Chen C, Matsumura K, et al. Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain.Synapse 1991; 9: 188–194.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Physics, School of Allied Health Sciences, Faculty of Medicine, Osaka University, 1-7, Yamadaoka, 565-0871, Suita, Osaka, Japan

    Rie Hosoi, Kaoru Kobayashi & Osamu Inoue

  2. Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan

    Junichi Ishida

Authors
  1. Rie Hosoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaoru Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junichi Ishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masatoshi Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Osamu Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Osamu Inoue.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hosoi, R., Kobayashi, K., Ishida, J. et al. Effect of sabcomeline on muscarinic and dopamine receptor binding in intact mouse brain. Ann Nucl Med 17, 123–130 (2003). https://doi.org/10.1007/BF02988450

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02988450

Key words

Search

Navigation